Abstract:Lipopolysaccharide (LPS) has essential role in the pathogenesis of D-galactosamine-sensitized animal models and alcoholic liver diseases of humans, by stimulating release of pro-inflammatory mediators that cause hepatic damage and intestinal barrier impairment. Oral pretreatment of probiotics has been shown to attenuate LPS-induced hepatic injury, but it is unclear whether the effect is direct or due to improvement in the intestinal barrier. The present study tested the hypothesis that pretreatment with probiotics enables the liver to withstand directly LPS-induced hepatic injury and inflammation. In a mouse model of LPS-induced hepatic injury, the levels of hepatic tumor necrosis factor-alpha (TNF-α) and serum alanine aminotransferase (ALT) of mice with depleted intestinal commensal bacteria were not significantly different from that of the control models. Pre-feeding mice for 10 days with Lactobacillus fermentum ZYL0401 (LF41), significantly alleviated LPS-induced hepatic TNF-α expression and liver damage. After LF41 pretreatment, mice had dramatically more L.fermentum-specific DNA in the ileum, significantly higher levels of ileal cyclooxygenase (COX)-2 and interleukin 10 (IL-10) and hepatic prostaglandin E2 (PGE2). However, hepatic COX-1, COX-2, and IL-10 protein levels were not changed after the pretreatment. There were also higher hepatic IL-10 protein levels after LPS challenge in LF41-pretreated mice than in the control mice. Attenuation of hepatic TNF-α was mediated via the PGE2/E prostanoid 4 (EP4) pathway, and serum ALT levels were attenuated in an IL-10-dependent manner. A COX-2 blockade abolished the increase in hepatic PGE2 and IL-10 associated with LF41. In LF41-pretreated mice, a blockade of IL-10 caused COX-2-dependent promotion of hepatic PGE2, without affecting hepatic COX-2 levels. In LF41-pretreated mice, COX2 prevented enhancing TNF-α expression in both hepatic mononuclear cells and the ileum, and averted TNF-α-mediated increase in intestinal permeability. Together, we demonstrated that LF41 pre-feeding enabled the liver to alleviate LPS-induced hepatic TNF-α expression and injury via a PGE2-EP4- and IL-10-dependent mechanism.

Lactobacillus salivarius LI01 encapsulated in alginate-pectin microgels ameliorates d-galactosamine-induced acute liver injury in rats

Lactobacillus Helveticus R0052 Alleviates Liver Injury by Modulating Gut Microbiome and Metabolome in D-galactosamine-treated Rats.

Administration of Lactobacillus Salivarius LI01 or Pediococcus Pentosaceus LI05 Improves Acute Liver Injury Induced by D-galactosamine in Rats.

Bifidobacterium adolescentis CGMCC 15058 alleviates liver injury, enhances the intestinal barrier and modifies the gut microbiota in d -galactosamine-treated rats

Protective Effect of Lactobacillus Salivarius Li01 on Thioacetamide‐induced Acute Liver Injury and Hyperammonaemia

<i>Bifidobacterium longum</i> R0175 Protects Rats against D-Galactosamine-Induced Acute Liver Failure

Protective effect of<i>Lactobacillus salivarius</i>Li01 on thioacetamide-induced acute liver injury and hyperammonaemia

Administration of Lactobacillus salivarius LI01 or Pediococcus pentosaceus LI05 prevents CCl 4 -induced liver cirrhosis by protecting the intestinal barrier in rats

Lactobacillus Reuteri DSM 17938 Alleviates D-Galactosamine-induced Liver Failure in Rats.

Effects of gut microflora on hepatic damage after acute liver injury in rats.

Pretreatment with Bacillus Cereus Preserves Against D-Galactosamine-Induced Liver Injury in a Rat Model

Multiple Intestinal Bacteria Associated with the Better Protective Effect of Bifidobacterium Pseudocatenulatum LI09 Against Rat Liver Injury.

Characteristics of the Intestinal Bacterial Microbiota Profiles in Bifidobacterium Pseudocatenulatum LI09 Pre-Treated Rats with D-galactosamine-induced Liver Injury

Bifidobacterium Longum R0175 Protects Mice Against APAP-induced Liver Injury by Modulating the Nrf2 Pathway.

Bifidobacterium longum R0175 Protects Rats against D-Galactosamine-Induced Acute Liver Failure

Bacillus amyloliquefaciens SC06 Attenuated Lipopolysaccharide-Induced acute liver injury by suppressing bile acid-associated NLRP3 inflammasome activation

Lactobacillus fermentum ZYL0401 Attenuates Lipopolysaccharide-Induced Hepatic TNF-α Expression and Liver Injury via an IL-10- and PGE2-EP4-Dependent Mechanism.

Characteristics of the Gut Microbiota in Bifidobacterium Catenulatum LI10 Pretreated Rats with Lower Levels of D-galactosamine-induced Liver Damage.

Protective Effect of Lactiplantibacillus plantarum 1201 Combined with Galactooligosaccharide on Carbon Tetrachloride-Induced Acute Liver Injury in Mice

Improved functionality of Ligilactobacillus salivarius Li01 in alleviating colonic inflammation by layer-by-layer microencapsulation

Antioxidative Single Atomic Nanocatalysts Facilitate Orally Administered Probiotic Inulin Gels for Acute Colitis Amelioration